thiamine has been researched along with Parkinson Disease in 9 studies
thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the potential clinical, restorative, and neuroprotective effects of long-term treatment with thiamine in Parkinson disease (PD)." | 7.81 | Long-Term Treatment with High-Dose Thiamine in Parkinson Disease: An Open-Label Pilot Study. ( Cardelli, LE; Colangeli, M; Costantini, A; Fancellu, R; Grossi, E; Jenner, C; Mondonico, S; Pala, MI; Proietti, S, 2015) |
| "To investigate the potential clinical, restorative, and neuroprotective effects of long-term treatment with thiamine in Parkinson disease (PD)." | 3.81 | Long-Term Treatment with High-Dose Thiamine in Parkinson Disease: An Open-Label Pilot Study. ( Cardelli, LE; Colangeli, M; Costantini, A; Fancellu, R; Grossi, E; Jenner, C; Mondonico, S; Pala, MI; Proietti, S, 2015) |
| "Thiamine has also been implicated in PD through its effects on L-type voltage-sensitive calcium channels (L-VSCC), matrix metalloproteinases (MMPs), prostaglandins (PGs), cyclooxygenase-2 (COX-2), reactive oxygen species (ROS), and nitric oxide synthase (NOS)." | 2.48 | Thiamine and Parkinson's disease. ( Lu'o'ng, Kv; Nguyên, LT, 2012) |
| "We performed the Unified Parkinson's Disease Rating Scale (UPDRS) and started a parenteral therapy with high doses of thiamine." | 1.39 | High-dose thiamine as initial treatment for Parkinson's disease. ( Colangeli, M; Compagnoni, L; Costantini, A; Pala, MI, 2013) |
| "Thiamine is an essential cofactor for several important enzymes involved in brain oxidative metabolism, such as the alpha-ketoglutarate dehydrogenase complex (KGDHC), pyruvate-dehydrogenase complex, and transketolase." | 1.30 | Cerebrospinal fluid levels of thiamine in patients with Parkinson's disease. ( Barcenilla, B; Berbel, A; de Bustos, F; Fernández-Vivancos, E; Gómez-Escalonilla, C; Hernánz, A; Jiménez-Jiménez, FJ; Molina, JA; Villanueva, C; Zurdo, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Håglin, L | 1 |
| Domellöf, M | 1 |
| Bäckman, L | 1 |
| Forsgren, L | 1 |
| Luong, KV | 1 |
| Nguyễn, LT | 2 |
| Costantini, A | 2 |
| Pala, MI | 2 |
| Compagnoni, L | 1 |
| Colangeli, M | 2 |
| Grossi, E | 1 |
| Mondonico, S | 1 |
| Cardelli, LE | 1 |
| Jenner, C | 1 |
| Proietti, S | 1 |
| Fancellu, R | 1 |
| Santos-García, D | 1 |
| Macías, M | 1 |
| Llaneza, M | 1 |
| Grande, M | 1 |
| de la Fuente-Fernández, R | 1 |
| Lu'o'ng, Kv | 1 |
| Balk, E | 1 |
| Chung, M | 1 |
| Raman, G | 1 |
| Tatsioni, A | 1 |
| Chew, P | 1 |
| Ip, S | 1 |
| DeVine, D | 1 |
| Lau, J | 1 |
| Gold, M | 1 |
| Hauser, RA | 1 |
| Chen, MF | 1 |
| Jiménez-Jiménez, FJ | 1 |
| Molina, JA | 1 |
| Hernánz, A | 1 |
| Fernández-Vivancos, E | 1 |
| de Bustos, F | 1 |
| Barcenilla, B | 1 |
| Gómez-Escalonilla, C | 1 |
| Zurdo, M | 1 |
| Berbel, A | 1 |
| Villanueva, C | 1 |
3 reviews available for thiamine and Parkinson Disease
| Article | Year |
|---|---|
The beneficial role of thiamine in Parkinson disease.
Topics: Animals; Humans; Parkinson Disease; Signal Transduction; Thiamine; Vitamins | 2013 |
Thiamine and Parkinson's disease.
Topics: Animals; Biomarkers; Cyclooxygenase 2; Humans; Oxidative Stress; Parkinson Disease; Reactive Oxygen | 2012 |
B vitamins and berries and age-related neurodegenerative disorders.
Topics: Aging; Alzheimer Disease; Animals; Blueberry Plants; Cognition; Disease Models, Animal; Folic Acid; | 2006 |
6 other studies available for thiamine and Parkinson Disease
| Article | Year |
|---|---|
Low plasma thiamine and phosphate in male patients with Parkinson's disease is associated with mild cognitive impairment.
Topics: Case-Control Studies; Cognitive Dysfunction; Female; Humans; Male; Parkinson Disease; Phosphates; Th | 2020 |
High-dose thiamine as initial treatment for Parkinson's disease.
Topics: Aged; Female; Humans; Male; Parkinson Disease; Thiamine; Treatment Outcome; Vitamin B Complex | 2013 |
Long-Term Treatment with High-Dose Thiamine in Parkinson Disease: An Open-Label Pilot Study.
Topics: Aged; Antiparkinson Agents; Disease Management; Dose-Response Relationship, Drug; Humans; Male; Midd | 2015 |
Serum vitamin B(12) and folate levels in Parkinson's disease patients treated with duodenal levodopa infusion.
Topics: Aged; Antiparkinson Agents; Female; Folic Acid; Humans; Infusions, Parenteral; Levodopa; Male; Middl | 2011 |
Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Female; Humans; Male; Middle Aged; Parkinson Dise | 1998 |
Cerebrospinal fluid levels of thiamine in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Dise | 1999 |